Edmond Mok

Edmond Mok has worked in the finance industry since 2014. From 2014 to 2016, they were the Head of Finance at Afferent Pharmaceuticals, which was acquired by Merck in June 2016. Edmond then worked as the Vice President of Finance (Consultant) at Applied Molecular Transport from 2015 to 2017. In 2017, they became the Interim CFO at R2M Pharma, Inc. and also started their own consulting firm, LaMok Consulting LLC. Through LaMok Consulting, they provided financial consulting services at the Vice President of Finance/CFO levels for early stage through IPO biotech companies. Edmond also managed the operational launches and growth of biotech clients from 1 employee up to 50 employees. Edmond has since worked as the Vice President of Finance (Consultant) at Neurona Therapeutics, Attenua Inc. (acquired by CODA), Curasen Therapeutics, Nura Bio (formerly Proneurotech), and Convelo Therapeutics. Edmond currently serves as the Vice President of Finance (Consultant) at MapKure LLC.

Edmond Mok attended the University of California, Berkeley from 1991 to 1993 and obtained a BA in Interdisciplinary Studies.